Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells

被引:18
作者
Ma, Ling-Di [1 ]
Zhou, Min [2 ]
Wen, Shi-Hong [1 ]
Ni, Cheng [1 ]
Jiang, Li-Jia [1 ]
Fan, Jing [1 ]
Xia, Lei [1 ]
机构
[1] NanjingMed Univ, Affiliated Hosp, Changzhou Peoples Hosp 2, Ctr Lab, Changzhou 213003, Peoples R China
[2] NanjingMed Univ, Affiliated Hosp, Changzhou Peoples Hosp 2, Dept Hematol, Changzhou 213003, Peoples R China
关键词
STAT3; RNA interference; CML; gene silencing; cell cycle; BCR-ABL; CONSTITUTIVE ACTIVATION; APOPTOSIS; EXPRESSION; PROTEINS; PHOSPHORYLATION; RESISTANCE; PATHWAYS; GROWTH;
D O I
10.3109/10428194.2010.483748
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Signal transducer and activator of transcription 3 (STAT3), a transcription factor, is constitutively activated in various types of cancers. Previous investigations have demonstrated that this overexpression of STAT3 in human malignancies plays important roles in maintaining the characteristics of malignant tumors by having an effect on proliferation, differentiation, and/or immortalization. Thus, inhibition of STAT3 expression could be a potent therapeutic approach in cancer treatment. In this study, we introduced STAT3 siRNA into the human chronic myelogenous leukemia (CML) K562 cell line, which has constitutive activation of STAT3, to elucidate the role of STAT3 in CML. The cells were transducted with STAT3 siRNA using lentivirus. FACS, real-time PCR, and Western blot were used to study changes in STAT3 expression levels in transducted cells by comparing with negative control siRNA lentivirus transduction. Knockdown of STAT3 by STAT3 siRNA caused a decrease in STAT3 protein level, inhibition of growth and proliferation, cell cycle blockade, visible morphologic changes, and induction of apoptosis in K562 cells. These findings demonstrate that STAT3 does indeed play a critical role in the survival of K562 cells, which may have potential application in designing molecular therapies for CML treatment.
引用
收藏
页码:1326 / 1336
页数:11
相关论文
共 29 条
[1]   The biology of chronic myelogenous leukemia: Implications for imatinib therapy [J].
Alvarez, Ricardo H. ;
Kantarjian, Hagop ;
Cortes, Jorge E. .
SEMINARS IN HEMATOLOGY, 2007, 44 (01) :S4-S14
[2]  
[Anonymous], 2012, Molecular Cloning: A Laboratory Manual
[3]   Expression of Cdc2 and cyclin B1 in Helicobacter pylori-associated gastric MALT and MALT lymphoma -: Relationship to cell death, proliferation, and transformation [J].
Banerjee, SK ;
Weston, AP ;
Zoubine, MN ;
Campbell, DR ;
Cherian, R .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (01) :217-225
[4]  
BARAN Y, 2007, HEMATOLOGY, V21, P1
[5]   Signal transducer and activator of transcription proteins in leukemias [J].
Benekli, M ;
Baer, MR ;
Baumann, H ;
Wetzler, M .
BLOOD, 2003, 101 (08) :2940-2954
[6]   Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance [J].
Bewry, Nadine N. ;
Nair, Rajesh R. ;
Emmons, Michael F. ;
Boulware, David ;
Pinilla-Ibarz, Javier ;
Hazlehurst, Lori A. .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (10) :3169-3175
[7]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[8]   STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation [J].
Chung, JK ;
Uchida, E ;
Grammer, TC ;
Blenis, J .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (11) :6508-6516
[9]   Gene delivery by lentivirus vectors [J].
Cockrell, Adam S. ;
Kafri, Tal .
MOLECULAR BIOTECHNOLOGY, 2007, 36 (03) :184-204
[10]   Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells [J].
Coppo, P ;
Dusanter-Fourt, I ;
Millot, G ;
Nogueira, MM ;
Dugray, A ;
Bonnet, ML ;
Mitjavila-Garcia, MT ;
Le Pesteur, D ;
Guilhot, F ;
Vainchenker, W ;
Sainteny, F ;
Turhan, AG .
ONCOGENE, 2003, 22 (26) :4102-4110